A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

NCT ID: NCT04614831

Last Updated: 2021-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4978 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-12

Study Completion Date

2021-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a Worldwide Survey on the Understanding of Psoriatic Disease among Patients with Psoriasis and Psoriatic Arthritis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a cross-sectional, quantitative online survey of patients with psoriasis with or without concomitant psoriatic arthritis. Following assessment of participant eligibility via a 5-minute online screener, the 25-minute internet-based survey will be conducted without any follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis, Psoriatic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psoriasis and Psoriatic Arthritis

The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who self-report to have been diagnosed with Psoriasis or Psoriasis and Psoriatic Arthritis before or at the time of data collection
2. Patients 18 years of age or older at the time of data collection
3. Patients who did not participate in surveys regarding Psoriasis or Psoriatic Arthritis in the last 4 weeks
4. Body Surface Area (BSA) of \>5 to \<10, with psoriasis affecting sensitive and/or prominent body parts: face, palms, hands, fingers, genitals, soles of feet or nails or a BSA of 10 and above, when psoriasis was at its worst
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigational Site

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAIN457A2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ACT-128800 in Psoriasis
NCT00852670 COMPLETED PHASE2
A Phase 4 Clinical Study of Brodalumab
NCT04183881 COMPLETED PHASE4
Psoriasis Longitudinal Assessment and Registry
NCT00508547 ACTIVE_NOT_RECRUITING